Strong Performance in Signals Software Business
The Signals Software business grew 20% organically in the quarter with even stronger SaaS performance and conversion. ARR over 40%, APV 12%, and net retention rate more than 110%.
Reproductive Health Business Growth
The reproductive health business grew in the mid-single digits year over year with newborn screening growing in the high single digits.
Adjusted Operating Margins and EPS
Generated 26.1% adjusted operating margins, modestly above expectations, and adjusted earnings per share of $1.18, which was $0.05 above the midpoint of guidance.
Capital Deployment and Share Repurchase
Strong focus on cash flow generation with $120 million free cash flow and $205 million spent repurchasing 2.3 million shares. New $1 billion share repurchase authorization received.
AI-Driven Innovations
Launch of new AI-focused software offerings and partnerships, including SignalsOne, Transcribe AI, and Phenologic AI, with continued robust development pipeline.
Strategic Partnerships
Collaborations with Genomics England and Sanofi to develop assays for early screening and improving diagnostics capabilities.
Environmental and Social Responsibility Achievements
6% reduction in emissions, 47% waste diversion, and 77% employee satisfaction rate. Received a triple-A rating from MSCI for ESG efforts.